HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, ...

HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.

HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac ...

Monitoring a patient’s heart condition is an extensive undertaking considering the current standard of care practices. Up until a few years ago, heart patients seeking to have their condition ...

The company was ranked second worldwide out of 243 companies evaluated in 12-lead ECG innovation in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam’s ranking underscores the rapid ...

Back in September, Apple announced that it had added new heart monitoring hardware to the Apple Watch Series 4, enabling the wearable to produce electrocardiogram (ECG) readings — with an FDA-approved ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...

Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...